Psoriatic arthritis
Drug research and approvals for psoriatic arthritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 86 studies of psoriatic arthritis are recruiting on ClinicalTrials.gov, Health Canada has authorized 49 drug trials for it since 2013, and the EU has 8 authorised medicines for it.
- Recruiting worldwide: 86
- Trials authorized in Canada: 49
- FDA orphan approvals: 0
- EU medicines: 8
- CAPN12 Gene Expression as a Molecular DiscriminatorNCT07946497 · Not reported · South Valley University · starts Oct 1, 2026
- Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or…NCT07908641 · Phase 1 · Amgen · starts Nov 18, 2026
- Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With Psoriatic Arthritis: A Case-Control…NCT07858591 · Not reported · Bursa Yuksek Ihtisas Training and Research Hospital · starts Sep 1, 2026
- A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic…NCT07801495 · Phase 2 · Novartis Pharmaceuticals · starts Oct 19, 2026
- HLA B Leader in Patients With Psoriatic ArthritisNCT07718815 · Not applicable · Centre Hospitalier Universitaire, Amiens · starts May 6, 2025
- Transcutaneous Auricular Vagus Nerve Stimulation in Psoriatic ArthritisNCT07653009 · Not applicable · Marmara University · starts Jun 2, 2026
- A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving…NCT07654751 · Phase 4 · Janssen Research & Development, LLC · starts Aug 7, 2026
- Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease…NCT07611747 · Phase 4 · Instituto de Investigación Marqués de Valdecilla · starts Apr 22, 2026
- Oxidative Stress in Autoimmune Rheumatic DiseasesNCT07536529 · Not reported · University of Thessaly · starts Oct 6, 2025
Approved 19
- SecukinumabInterleukin 17A inhibitor
- AdalimumabTNF-alpha inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- GolimumabTNF-alpha inhibitor
- ApremilastPhosphodiesterase 4 inhibitor
- GuselkumabInterleukin-23 inhibitor
- EtanerceptTNF-alpha inhibitor
- UstekinumabInterleukin-12 inhibitor
- TofacitinibJanus Kinase (JAK) inhibitor
- IxekizumabInterleukin 17A inhibitor
- RisankizumabInterleukin-23 inhibitor
- InfliximabTNF-alpha inhibitor
- LeflunomideDihydroorotate dehydrogenase inhibitor
- AbataceptT-lymphocyte activation antigen CD86 inhibitor
- Certolizumab pegolTNF-alpha inhibitor
- PrednisoneGlucocorticoid receptor agonist
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- Isopropyl alcohol
Phase 3 7
- BimekizumabInterleukin 17A inhibitor
- FilgotinibTyrosine-protein kinase JAK1 inhibitor
- BrodalumabInterleukin-17 receptor A antagonist
- CravacitinibTyrosine-protein kinase TYK2 negative allosteric modulator
- UpadacitinibTyrosine-protein kinase TYK2 inhibitor
- SulfasalazineArachidonate 5-lipoxygenase inhibitor
- OnerceptTNF-alpha inhibitor
Phase 2 12 of 16
- RemtolumabTNF-alpha inhibitor
- IzokibepInterleukin 17A inhibitor
- Fludarabine
- AlefaceptT-cell surface antigen CD2 inhibitor
- Dimethyl fumarateKelch-like ECH-associated protein 1 inhibitor
- DronabinolCannabinoid CB1 receptor agonist
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- ClazakizumabInterleukin-6 inhibitor
- HOKT3T-cell surface glycoprotein CD3 epsilon chain inhibitor
- BrepocitinibTyrosine-protein kinase TYK2 inhibitor
- M-1095Interleukin 17A inhibitor
- NeihulizumabP-selectin glycoprotein ligand 1 inhibitor
Phase 1 or earlier 6
- RituximabB-lymphocyte antigen CD20 binding agent
- EfalizumabIntegrin alpha-L/beta-2 (LFA-1) inhibitor
- PG-102Tumor necrosis factor receptor superfamily member 5 inhibitor
- PerakizumabInterleukin 17A inhibitor
- Gamcemetinib
- Fapi GA-68
How its trials ended
525 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 168 whose ending is known, 70% met their primary endpoint, 4% missed it and 26% stopped early.
- Completed, result not reported17734%
- Ongoing14027%
- Met its primary endpoint11822%
- Status unknown408%
- Stopped: other or unclear224%
- Stopped: sponsor or business decision82%
- Stopped: enrollment or feasibility71%
- Missed its primary endpoint61%
- Stopped: lack of efficacy51%
- Stopped: funding2<1%
| Aug 11, 2026 | A randomized, double-blind, placebo-controlled, multicenter phase 2a/b study assessing the efficacy, safety and tolerability of DDY391 in participants with…DDY391 | Novartis Pharmaceuticals | Pending |
| May 13, 2026 | A phase 3, multicenter, long-term extension study to evaluate the long-term safety, tolerability, and efficacy of zasocitinib (TAK-279) in subjects with active…Zasocitinib (TAK-279) | Takeda Pharmaceuticals USA | Pending |
| Apr 13, 2026 | A phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tulisokibart in participants with psoriatic arthritisTulisokibart (MK-7240) | Merck & Co. (MSD) | Ongoing |
| Apr 11, 2025 | A phase 2 multicenter, randomized, platform study of targeted therapies for the treatment of adult subjects with active psoriatic arthritisLutikizumab (ABT-981) / Risankizumab (ABBV-066) | AbbVie | Ongoing |
| Mar 5, 2025 | A multi-center, randomized, double-blind, and placebo-controlled phase 3 study to evaluate the efficacy and safety of zasocitinib (TAK-279) in subjects with…Zasocitinib (TAK-279) | Takeda Pharmaceuticals USA | Ongoing |
| Feb 7, 2025 | A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of JNJ-77242113 for the treatment of…Icotrokinra (JNJ-77242113) | Johnson & Johnson | Ongoing |
| Nov 20, 2024 | A phase 3, parallel-group, randomized, double-blind, 4-arm, placebocontrolled, multicenter study with risankizumab as active reference arm, to investigate the…Sonelokimab | Moonlake Immunotherapeutics AG | Ongoing |
| Nov 19, 2024 | A phase 3, parallel-group, randomized, double-blind, 3-arm, placebocontrolled, multicenter study to investigate the efficacy and safety of subcutaneous…Sonelokimab | Moonlake Immunotherapeutics AG | Ongoing |
| Sep 6, 2024 | A multicenter, randomized, double-blind, risankizumab-controlled, parallel-group study to evaluate the efficacy and safety of bimekizumab in adult study…Bimekizumab | UCB | Closed |
| Jul 19, 2024 | Open-label, single-arm trial to evaluate the pharmacokinetics and safety of bimekizumab in pediatric study participants from 2 to less than 18 years of age…Bimekizumab | UCB | Ongoing |
| Apr 19, 2024 | Apremilast AccordApremilast · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Mar 24, 2023 | SotyktuDeucravacitinib | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| Aug 20, 2021 | BimzelxBimekizumab | UCB Pharma S.A. | EMA ↗ |
| May 18, 2018 | ZesslyInfliximab · biosimilar | Sandoz GmbH | EMA ↗ |
| Jan 15, 2015 | OtezlaApremilast | Amgen Europe B.V. | EMA ↗ |
| Nov 28, 2010 | Leflunomide ratiopharmLeflunomide · generic | Ratiopharm GmbH | EMA ↗ |
| Jan 8, 2010 | Leflunomide Zentiva (previously Leflunomide Winthrop)Leflunomide | Zentiva k.s. | EMA ↗ |
| Sep 2, 1999 | AravaLeflunomide | Sanofi-aventis Deutschland GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA